2017 HCV Virtual Patient: Clinical Management of Key Treatment Decisions

About the Program

• Program Overview
• Target Audience
• Learning Objectives
• Faculty
• Physician Continuing Medical Education
• Credit Designation
• Disclosure of Conflicts of Interest
• Instructions for Participation and Credit
• Disclosure of Unlabeled Use
• Disclaimer

Program Overview

Chronic HCV (CHC) is a common viral infection that afflicts millions of people in the United States. It is a significant public health issue, because CHC can evolve into states that are associated with chronic inflammation, progressive fibrosis, cirrhosis, and malignancy. In recent years, significant progress has been made in the treatment of CHC, but many clinicians who manage patients infected with HCV are not aware of the full range of complex and emerging treatment options available or how to apply them to various patient scenarios. Due to the rapidly changing landscape in CHC management, this situation can significantly affect the treatment of patients with HCV infection and the quality of the care they receive, potentially affecting patient outcomes, increasing morbidity, mortality, and treatment costs.

The HCV Virtual Patient program is an interactive, case-based program featuring real-world case scenarios discussed by HCV thought leaders.  Participants will be asked to assess and treat a variety of HCV-infected patient types with the direction and consultation of HCV thought leaders. This program provides important information that can be directly applied to clinical practice, thereby increasing the delivery of optimal care to patients with HCV infection in the United States.

Back to Top

Target Audience

This activity has been designed to meet the educational needs of physicians, physician assistants, advanced practice nurses and other health care professionals involved in the care of patients with HCV infection.

Back to Top

Learning Objectives

After completing this activity, participants should be better able to:

• Take steps to improving testing, diagnosis and linkage to care of chronic hepatitis C (CHC) patients, espeically those in underserved communities
• Explain the long-term consequences of untreated CHC
• Implement individualized antiviral treatment based on patient characteristics using available treatment options for patients with CHC
• Develop optimal approaches for managing adverse events to facilitate adherence in patients being treated for CHC
• Manage drug-drug interactions and other treatment issues experienced by patients with CHC patients and patients with HCV/HIV co-infection

Release Date: June 9, 2017

Expiration Date: June 9, 2018

Estimated time to complete each Virtual Patient Case:  30-90 minutes

Media: Internet

Back to Top

Faculty

Physician Continuing Medical Education

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and ViralEd, Inc. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

For Cases: 1, 3, 6, 7

For Cases: 2, 4, 9, 10

For Case 5

For Case 8

Back to Top

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:

Oluwatoyin M. Adeyemi, MD

• Consulting Fees: Gilead, ViiV
• Contracted Research: Gilead, AbbVie

Brenda Appolo PA-C, MHS

• Consulting Fees: Merck, Gilead, Intercept
• Fees for Non-CME/CE Services Received Directly from a Commercial Interest or thier Agents (e.g., speakers' bureaus: Merck, Gilead, Intercept

• Consulting Fees: Merck, Gilead, Echosens, Ligand, Janssen, Shionogi
• Employee/Salary: Spring Bank Pharmaceuticals
• Other: Director-TRIO Healthcare
• Stock: Allurion, Spring Bank Pharmaceuticals

• Consulting Fees: Gilead, AbbVie, Merck
• Fees for Non-CME/CE Services Received Directly from a Commercial Interest or thier Agents (e.g., speakers' bureaus: Gilead, AbbVie, Merck
• Contracted Research: Gilead, AbbVie, Merck

David Kaplan, MD

• Contracted Research: Bayer Healthcare, Inovio

Paul Kwo, MD

• Consulting Fees: Abbvie, Quest, CVS, BMS, Gilead, Janssen, Merck, Alnylam
• Contracted Research: Abbvie, BMS, Gilead, Janssen, Merck, Contanus, ESAI
• Other (DSMB): Inovio

Instructions for Participation and Credit

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer